Product Details

Uniprot No.

Target Names

Alternative Names

actin-dependent regulator of chromatin subfamily F member 1 antibody; ARI1A_HUMAN antibody; ARID domain containing protein 1A antibody; ARID domain-containing protein 1A antibody; ARID1A antibody; AT rich interactive domain 1A (SWI like) antibody; AT rich interactive domain 1A antibody; AT rich interactive domain containing protein 1A antibody; AT-rich interactive domain-containing protein 1A antibody; B120 antibody; BAF250 antibody; BAF250A antibody; BM029 antibody; brain protein 120 antibody; BRG1 associated factor 250 antibody; BRG1 associated factor 250a antibody; BRG1-associated factor 250 antibody; BRG1-associated factor 250a antibody; C1ORF4 antibody; chromatin remodeling factor p250 antibody; chromosome 1 open reading frame 4 antibody; ELD antibody; hELD antibody; hOSA1 antibody; matrix-associated antibody; MRD14 antibody; Osa homolog 1 antibody; OSA1 antibody; OSA1 nuclear protein antibody; P270 antibody; SMARCF1 antibody; SWI like protein antibody; SWI SNF complex protein p270 antibody; SWI-like protein antibody; SWI/SNF complex protein p270 antibody; SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily f, member 1 antibody; SWI/SNF-related antibody

Species Reactivity

Human

Immunogen

A synthesized peptide from human ARID1A protein

Immunogen Species

Homo sapiens (Human)

Conjugate

Non-conjugated

Clonality

Monoclonal

Isotype

Rabbit IgG

Clone No.

22A7

Purification Method

Affinity-chromatography

Concentration

It differs from different batches. Please contact us to confirm it.

Buffer

Rabbit IgG in 10mM phosphate buffered saline , pH 7.4, 150mM sodium chloride, 0.05% BSA, 0.02% sodium azide and 50% glycerol.

Form

Liquid

Tested Applications

ELISA, IHC, FC

Recommended Dilution

Application	Recommended Dilution
IHC	1:50-1:200
FC	1:50-1:200

Protocols

ELISA Protocol
Immunohistochemistry (IHC) Protocol
Flow Cytometry (FC) Protocol

Troubleshooting and FAQs

Antibody FAQs

Storage

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Lead Time

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Description

ARID1A serves as a critical subunit of the SWI/SNF chromatin remodeling complex, where it functions as BAF250a to regulate gene expression through ATP-dependent nucleosome repositioning. This protein plays essential roles in cell cycle control, DNA repair, and differentiation, making it a significant focus in cancer research given its frequent mutation across multiple tumor types, including ovarian clear cell carcinoma, endometrial cancer, and gastric adenocarcinoma.

This recombinant monoclonal antibody, clone 22A7, offers the experimental consistency that demanding research protocols require. Developed through recombinant technology with a defined sequence, it eliminates the lot-to-lot variability that can compromise longitudinal studies or multi-site collaborations. The rabbit host and monoclonal nature ensure high specificity for human ARID1A, providing reliable detection across your experimental timeline.

Validation studies demonstrate robust performance in immunohistochemistry, with successful staining confirmed in paraffin-embedded human kidney tissue and human lung cancer specimens at 1:100 dilution using citrate buffer antigen retrieval. This tissue-level validation proves particularly valuable for researchers investigating ARID1A expression patterns in both normal and malignant contexts. Flow cytometry applications have been validated using SH-SY5Y neuroblastoma cells, showing clear positive signal separation from isotype controls, enabling quantitative analysis of ARID1A expression at the single-cell level.

The antibody arrives purified by affinity chromatography in a glycerol-containing buffer optimized for long-term storage stability. Whether you are characterizing ARID1A loss in tumor samples, investigating chromatin remodeling dynamics, or exploring signal transduction pathways influenced by SWI/SNF complex function, this antibody provides a dependable tool for advancing your research objectives.

Usage

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Target Background

Function

Involved in transcriptional activation and repression of select genes by chromatin remodeling (alteration of DNA-nucleosome topology). Component of SWI/SNF chromatin remodeling complexes that carry out key enzymatic activities, changing chromatin structure by altering DNA-histone contacts within a nucleosome in an ATP-dependent manner. Binds DNA non-specifically. Belongs to the neural progenitors-specific chromatin remodeling complex (npBAF complex) and the neuron-specific chromatin remodeling complex (nBAF complex). During neural development a switch from a stem/progenitor to a postmitotic chromatin remodeling mechanism occurs as neurons exit the cell cycle and become committed to their adult state. The transition from proliferating neural stem/progenitor cells to postmitotic neurons requires a switch in subunit composition of the npBAF and nBAF complexes. As neural progenitors exit mitosis and differentiate into neurons, npBAF complexes which contain ACTL6A/BAF53A and PHF10/BAF45A, are exchanged for homologous alternative ACTL6B/BAF53B and DPF1/BAF45B or DPF3/BAF45C subunits in neuron-specific complexes (nBAF). The npBAF complex is essential for the self-renewal/proliferative capacity of the multipotent neural stem cells. The nBAF complex along with CREST plays a role regulating the activity of genes essential for dendrite growth.

Gene References into Functions

Cells lacking ARID1A show enhanced AURKA transcription, which leads to the persistent activation of CDC25C, a key protein for G2/M transition and mitotic entry. PMID: 30097580
the correlation between the loss of ARID1A immunoreactivity and reduced ARID1B levels indicates that ARID1B could be an attractive target for anti-cancer therapy. PMID: 29890703
these data suggest that the combined treatment with PI3K inhibitor BKM120 and PARP inhibitor olaparib may be a promising therapeutic regimen for the treatment of gastric cancer, and ARID1A deficiency could serve as a potential predictive therapeutic biomarker. PMID: 29767248
Although Genome-Wide Association studies have not been carried out in the field of alcohol-related hepatocellular carcinoma (HCC), common single nucleotide polymorphisms conferring a small increase in the risk of liver cancer risk have been identified. Specific patterns of gene mutations including CTNNB1, TERT, ARID1A and SMARCA2 exist in alcohol-related HCC. [review] PMID: 28296015
The authors find that ARID1A has a dominant role in maintaining chromatin accessibility at enhancers, while the contribution of ARID1B is evident only in the context of ARID1A mutation. PMID: 28967863
ARID1A and human epidermal growth factor receptor-2 (Her-2) status were found to be independent prognostic factors of both overall survival (OS) and disease free survival (DFS). PMID: 28543794
ARID1A expression loss was associated with poor overall survival in Asians with gastric cancer. [meta-analysis] PMID: 27354232
the significant correlation was achieved between the negative ARID1A expression and the FIGO stage of endometrium-related gynecological cancers, but not the other characteristics. PMID: 28466574
This metaanalysis indicated that Gastric Cancer or Colorectal Cancer with ARID1A alteration might be a marker of poor prognosis. The ARID1A alteration of Gastric Cancer may result from different epigenetic factors. PMID: 28937020
Low ARID1A expression is associated with clear cell and endometrioid carcinoma of the ovary and the endometrium. PMID: 29451900
Loss of PTEN and ARID1A expression is highly specific for malignancy in effusion pathology PMID: 29170871
We propose a signaling cascade involving ARID1A, GADD45B and DUSP1 as mediators of the romidepsin effects in GCC cells. PMID: 27572311
head and neck squamous cell carcinoma patients with tumors having high level of miR-31 expression and high levels of Nanog/OCT4/Sox2/EpCAM expression, together with low level of ARID1A expression, were found to have the worst survival PMID: 27528032
loss of ARID1A leads to accumulation of ROS; elesclomol may be used to target ARID1A-mutant gynecologic cancer cells PMID: 27486766
genomic data and clinical features of four patients carrying a small 1p36.11 microduplication encompassing the complete ARID1A gene PMID: 27906199
Data show that 38 samples of 82 ovarian clear cell carcinoma (CCC) specimens presented no BAF250a expression, and 50 samples exhibited the loss of at least one subunit of the SWI/SNF complex. PMID: 27340867
Partial loss (i.e. in one tissue section some cells stained positive for BAF250a while other cells, usually an adjacent group, were negative) of BAF250a protein was identified in 36% (9/25) of rectovaginal DIE samples, 40% (2/5) of endometriosis lesions involving the PSLN, 30% (6/20) of endometriomas, and also in 25% (5/20) of endometrium from controls. PMID: 26832958
In the very high-risk Bladder Cancer patients , several genes had a higher frequency of mutations than reported in the The Cancer Genome Atlas database, including ARID1A . Mutation associations with receipt of neoadjuvant chemotherapy, nodal involvement, metastatic disease development, and survival were analyzed. PMID: 27520487
Tumors accumulate ARID1A mutations. PMID: 27172896
ARID1A silencing could significantly enhance the capability of migration and invasion in lentivirus miR-144-3p cells. PMID: 29073615
we identified concurrent ARID1A and ARID1B inactivating mutations with consequent loss of protein expression in the undifferentiated component of approximately one-quarter of dedifferentiated endometrial and ovarian carcinomas PMID: 27562491
Our study provides a novel insight into the modulatory function and mechanism of ARID1A in PI3K/AKT signaling in gastric cancer PMID: 27323812
Of the 34 undifferentiated endometrial carcinomas examined, 17 (50%) exhibited SWI/SNF complex inactivation, with 11 tumors showing complete loss of both ARID1A and ARID1B, 5 showing complete loss of BRG1 and 1 showing complete loss of INI1. Ten of the remaining 17 undifferentiated carcinomas showed the following alterations: 5 tumors (15%) showed loss of ARID1A only with intact ARID1B, BRG1, and INI1 expression. PMID: 28863077
BAF250a loss in AE is consistently associated with the development of BAF250a-negative endometriosis-associated cancers and appears to be an early event in most of these cases. PMID: 27051059
Transcriptome analysis revealed ARID1A knockdown led to miR-503 upregulation. CDKN2A was identified as a target of miR-503, which contributes to cell senescence. Thus, the data suggests that ARID1A deficiency promote KRAS(G12D)-driven pancreatic tumorigenesis through miR-503/CDKN2A-mediated senescence. PMID: 28942143
ARID1A may be a primary driver of carcinogenesis in a subset of esophageal adenocarcinomas PMID: 28440661
ARID1A mutation inactivates the apoptosis-promoting function of p53 by upregulating HDAC6, indicating that pharmacological inhibition of HDAC6 is a therapeutic strategy for ARID1A-mutated cancers. PMID: 28737768
ARID1A mutation can be an early stage event in the oncogenic transformation of endometriosis cells giving rise to ovarian clear cell carcinoma. PMID: 28483516
ARID1A expression is significantly decreased in higher stages of urothelial carcinoma and its aggressive variants. PMID: 27137986
Our data suggests that deficiency or loss of functional mutations of ARID1A in HCC cells might contribute to the increased activity of certain cancer-promoting lncRNAs. PMID: 28716731
ARID1A loss lacks prognostic significance in early stage colorectal adenocarcinoma. PMID: 26980037
ARID1A may play an important role in the early events of gastric carcinogenesis. PMID: 28031120
loss of ARID1A is more common in advanced GC and is related to EBV positivity and MMR deficiency PMID: 26067140
ARID1A protein and mRNA expression was lower in intrahepatic cholangiocarcinoma tissue than in normal liver tissue. PMID: 27433094
Most HCCs had an increased level of ARID1A mRNA. PMID: 26589513
loss of ARID1A protein expression found in TU-OC-2 cells. PMID: 26960408
Inactivating mutations in ARID1A may be involved in a novel pathway of carcinogenesis in biliary carcinomas PMID: 27334809
loss of ARID1A shortened time to cancer-specific mortality, and to recurrence of cancer when adjusting for potential confounders (Meta-Analysis) PMID: 26384299
loss of ARID1A protein expression caused by inactivating mutations reactivates TERT transcriptional activity and confers a survival advantage of tumor cells by maintaining their telomeres. PMID: 26953344
All cases with ARID1A expression are overlapped with H2B high expression. Among 15 cases with ARID1A and H2B coexpression, 13 are invasive ductal carcinoma and 2 are mucinous carcinoma. Our results indicate that ARID1A gene may be involved in carcinogenesis of some subtypes of breast cancer. PMID: 26904685
The action of ARID1A in carcinogenesis differs between adenofibroma-related clear cell carcinoma and endometriosis-related clear cell carcinoma. PMID: 25913291
we focus on the relationships of ARID1A mutations with ovarian and endometrial cancers[review] PMID: 26572704
analysis of ARID1A, CDH1, cMET and PIK3CA expression and target-related microRNA expression in gastric cancer PMID: 26334097
The loss of ARID1A was correlated with late-stage and endometriosis-associated ovarian clear cell carcinoma. ARID1A expression may predict the risk of recurrence. PMID: 26945423
Complete or partial loss of ARID1A expression is considered an independent poor prognostic factor in patients with gastric cancer. PMID: 26826411
ARID1A positively regulates Klf15 expression with PGR to inhibit epithelial proliferation at peri-implantation. Our results suggest that Arid1a has a critical role in modulating epithelial proliferation which is a critical requisite for fertility PMID: 26378916
Our results indicate that the Arid1a tumour suppressor gene has a key role in regulating ovarian endometrioid carcinoma differentiation PMID: 26279473
Arid1A role in genome-wide transcriptional regulation by SWI/SNF complexes. PMID: 26716708
Identification of this undescribed functional NLS within ARID1A contributes vital insights to rationalize the impact of ARID1A missense mutations observed in patient tumors. PMID: 26614907
Data showed that ARID1A interacts with ATR via its C-terminal region, which mediates its recruitment to DNA double-strand breaks. PMID: 26069190

Hide All

Involvement in disease

Coffin-Siris syndrome 2 (CSS2)

Subcellular Location

Nucleus.

Tissue Specificity

Highly expressed in spleen, thymus, prostate, testis, ovary, small intestine, colon, and PBL, and at a much lower level in heart, brain, placenta, lung, liver, skeletal muscle, kidney, and pancreas.

Database Links

HGNC: 11110

OMIM: 603024

KEGG: hsa:8289

STRING: 9606.ENSP00000320485

UniGene: Hs.468972

Message

Product >> Product Name：
Product >> Code：
Name： *
Email： *
Company/Organization：
Phone：
Since emails may get flagged by spam filters occasionally, we recommend leaving your phone number as a precaution. Your information is safe with us.
Question/Comment： *
Your Region： *
I'd like to receive email newsletters from Cusabio

Yes

No
How do you know CUSABIO?

Email

Distributor

Search engine

Advertisement

Others
CAPTCHA verification：
Please enter the characters shown. Click the image to refresh if unclear.

Code	CSB-RA164774A0HU
Size	US$210
	Order now
Image	IHC image of CSB-RA164774A0HU diluted at 1:100 and staining in paraffin-embedded human kidney tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a Goat anti-rabbit polymer IgG labeled by HRP and visualized using 0.05% DAB. IHC image of CSB-RA164774A0HU diluted at 1:100 and staining in paraffin-embedded human lung cancer performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a Goat anti-rabbit polymer IgG labeled by HRP and visualized using 0.05% DAB. Overlay Peak curve showing SH-SY5Y cells stained with CSB-RA164774A0HU (red line) at 1:100. The cells were fixed in 4% formaldehyde and permeated by 0.2% TritonX-100 for 10min. Then 10% normal goat serum to block non-specific protein-protein interactions followed by the antibody (1ug/110⁶cells) for 45min at 4℃. The secondary antibody used was FITC-conjugated goat anti-rabbit IgG (H+L) at 1/200 dilution for 35min at 4℃.Control antibody (green line) was Rabbit IgG (1ug/110⁶cells) used under the same conditions. Acquisition of >10, 000 events was performed.
Have Questions?	Leave a Message or Start an on-line Chat

ARID1A Recombinant Monoclonal Antibody

Product Details

Related Products

Customer Reviews and Q&A

Target Background